Sep 10, 2019
I-Mab Biopharma and Junshi Biosciences Announce Collaboration to Evaluate TJD5 in Combination with Toripalimab for the Treatment of Patients with Cancers in China
Aug 01, 2019
I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in a Phase 1 Trial of the CD73 Antibody TJD5 in the U.S. in Patients with Advanced Solid Tumors
Jul 13, 2019
I-Mab Announces IND Approval for Its Proprietary TJC4, A Potentially Differentiated CD47 Antibody, to Initiate Clinical Trials in China
Jul 10, 2019
MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China
Jun 25, 2019
I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States
Apr 29, 2019
I-Mab Biopharma and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Study of TJ202/MOR202 in Multiple Myeloma
Apr 16, 2019
I-Mab Biopharma and WuXi Biologics Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs
Apr 07, 2019
I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical Announce Strategic Collaboration Agreement with Biodextris and a Boston-Based, Leading Academic Medical Center
Mar 19, 2019
I-Mab Biopharma and MorphoSys Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma
Mar 05, 2019
I-Mab Biopharma Announces the Achievement of First Patient Dosing in Phase 1b/2a China Trial of TJ107 for Cancer and Chemotherapy-induced Lymphopenia
Feb 01, 2019
I-Mab Biopharma and Bio-Cancer Treatment International Announce Intention for Collaboration on Arginine Depletion Therapy and Biomarker Study, with Plans for I-Mab to Establish a Translational Medicine Lab in Hong Kong
Jan 28, 2019
I-Mab Receives IND Approval from the US FDA to Initiate Clinical Trials for Its Proprietary TJC4, a Potential Global Best-in-Class Anti-CD47 Monoclonal Antibody
Jan 22, 2019
I-Mab Biopharma Receives U.S. FDA IND Clearance for Proprietary CD73 Antibody TJD5
Dec 23, 2018
I-Mab Receives U.S. FDA IND Approval for Proprietary Anti-GM-CSF Monoclonal Antibody TJM2
Nov 29, 2018
TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs
Nov 15, 2018
MorphoSys and I-Mab Sign Strategic Partnering Agreement for MorphoSys's Novel Immuno-Oncology Agent MOR210
Nov 02, 2018
I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy
Oct 12, 2018
First Patient Dosing achieved in Mainland China in a Phase II Multi-regional clinical trial (MRCT)
Sep 19, 2018
I-Mab Wins Frost & Sullivan "2018 Best R&D Innovator Award (Biopharma Category)"
Aug 09, 2018
I-Mab's Announces China Clinical Trial Approval of Long-acting hGLP-1 to Treat Type 2 Diabetes